 SAN CARLOS, Calif., April 08, 2022 GLOBE NEWSWIRE -- Atreca, Inc. Atreca NASDAQ: BCEL, a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that management will present at the following upcoming virtual investor conferences: 